We have only just started to understand how our brains clean themselves, but columnist Helen Thomson finds promising evidence ...

Up to $500 million a year should benefit local families, but might flow out of state to needy kids elsewhere — unless Hochul ...

The research team traced the CSF drainage pathways from the anterior and middle parts of the brain. Using genetically engineered mice that express fluorescent proteins in their lymphatic vessels, they ...

A local Secret Santa is giving $1 million to deserving people in eastern Idaho this holiday season. Every day, from now until ...

Researchers have shown that glioblastoma can take over the skull marrow to dissolve bone and feed its own growth, suggesting ...

Savara Inc. recently reported that the European Patent Office intends to grant a patent covering the liquid formulation of MOLBREEVI, its orally inhaled recombinant human GM-CSF for treating ...

The FLAMINGO-01 DSMB met twice in 2025, most recently in December 2025, and recommended to continue the study as is without modification. The Steering Committee also met at SABCS 2025 and discussed ...

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...

Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

The immunotherapies used to treat melanoma now include well-established drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) and newer ones such as Amtagvi (lifileucel), which uses T cells ...